PARI's optimized Investigational eFlow® Technology nebulizer delivering well tolerated aerosols of AR-501 in Aridis´ Phase 1/2a clinical trial
PARI Pharma’s proprietary aerosol delivery platform, eFlow Technology, continues its long track record of success with Aridis Pharmaceuticals.